Methodology of 3H-spiperone binding to lymphocytes.
Alterations in lymphocyte binding capacity for the dopamine antagonist 3H-spiperone may be of great interest in psychiatric and neurological disorders: an increase in capacity noted in lymphocytes of schizophrenic patients and their families may well turn out to be a phenotypic vulnerability marker. Since the 3H-spiperone binding assay with lymphocytes does not fulfill common receptor-binding assay criteria and depends more on crucial analytical conditions, shortcomings in binding assay might possibly lead to irreproducible results. A detailed methodological description of the binding assay and subsequent calculations has therefore been given in this paper.
Bondy
B
B
Psychiatric Hospital, University of Munich, F.R.G.
Ackenheil
M
M
Engel
R R
RR
D001667:Binding, Competitive / Q000502:physiology; D002069:Butaclamol / Q000493:pharmacokinetics; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism*; D011954:Receptors, Dopamine / Q000378:metabolism*; D012984:Software; D013134:Spiperone / Q000493:pharmacokinetics*
D011954:Receptors, Dopamine; C031611:spiroperidol receptor; D013134:Spiperone; D002069:Butaclamol